002755 Beijing Aosaikang Pharmaceutical
- 10.83
- -0.04-0.37%
Beijing Aosaikang Pharmaceutical News
Express News | Osecon: The subsidiary obtained a drug registration certificate for injectable isaconazole sulfate
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
The biomedical sector fluctuated higher, and Weixinkang went up and down in a straight line. Osecon was previously closed, and Aoxiang Pharmaceutical, Heyuan Biotech, Haichuang Pharmaceutical, and Bohui Innovation had the highest gains.
Osecon (002755.SZ): net loss of 149 million yuan in 2023
On April 28, Ge Longhui (002755.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,443 million yuan, a year-on-year decrease of 22.92%; net loss attributable to shareholders of listed companies was 149 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 227 million yuan; basic loss per share was 0.16 yuan/share.
Osecon (002755.SZ) announced first-quarter results, net profit of 31.5547 million yuan, turning a loss into a profit
According to Zhitong Finance App News, Osecon (002755.SZ) released its report for the first quarter of 2024. The company's operating income was 448 million yuan, up 32.47% year on year; net profit attributable to shareholders of listed companies was 31,5447 million yuan, which turned a loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.361 million yuan; basic income per share was 0.03 yuan/share.
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healt
Pharmaceutical stocks continued to rise in the afternoon. Osecon moved up the market. BeiGene Shenzhou and Hengrui Pharmaceuticals both rose more than 4%, and the weights of the pharmaceutical industry such as Kangde, Aier Ophthalmology, and Mindray Healthcare collectively strengthened.
Osecon (002755.SZ): The subsidiary will present clinical research data for the innovative drug ASKC202 at the 2024 AACR Annual Meeting
Gelonghui, April 8, 丨 Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, first announced phase I (ASKC202-001) dose-increasing clinical trial data in the form of a poster at the American Association for Cancer Research (AACR) annual meeting on April 8, 2024.
The innovative medicine sector rebounded and Osecon rose or stopped
Gelonghui, March 27 | Osecon rose and stopped, and Xiangxue Pharmaceutical, First Pharmaceutical Holdings, Yakshi Technology, and Chengdu Pioneer followed suit. According to the news, at the 2024 Annual Meeting of the China Development High-Level Forum held a few days ago, major industry experts said that the development of China's biomedical industry already has a good foundation, and an ecological environment encouraging the development of innovative drugs is being formed.
A-share innovative drug concept stocks fell, and Osecon fell more than 4%
Gelonghui, March 18 | Osecon fell more than 4%, Sailong Pharmaceutical and Baiyunshan fell more than 3%, and Luoxin Pharmaceutical and Pharmaceutical Kangde followed suit.
Osecon (002755): Waiting for breakthroughs in innovation-driven transformation
The company is a comprehensive pharmaceutical company on the eve of innovation and implementation. The company started with proton pump inhibitor (PPI) injections and is a leading company in this field. In 2019-2022, due to collection, the company's performance declined. 2023 bottomed out
Beijing Aosaikang Pharma's Unit Gets Nod to Market Delafloxacin for Injection
Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, obtained approval from China's National Medical Products Administration to market delafloxacin for injection, ac
Express News | Osecon: The subsidiary obtained a notice of acceptance of the application for drug registration and marketing approval for injectable delafloxacin.
Osecon (002755.SZ) issued an advance loss. It is expected to lose a huge loss of 140 million yuan to 200 million yuan in 2023, and the loss will narrow
Osecon (002755.SZ) released the 2023 annual performance forecast, and the company expects 2023 to fall under the above...
Express News | Osecon: Subsidiary dexlansoprazole, etrapoprazole ethanolamine, and torrimifene citrate approved for marketing
Express News | Osecon: Phase III study of the bioinnovative drug ASKB589 completed its first patient administration in China
Aosaikang Pharmaceutical Registers Breast Cancer Drug
Beijing Aosaikang Pharmaceutical (SHE:002755) has obtained a registration certificate for its drug aimed at treating metastatic breast cancer in postmenopausal women, according to a filing on Tuesday.
Osecon (002755.SZ): Subsidiary torimifene citrate tablets obtained drug registration certificate
Gelonghui, January 22丨Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for torimifene citrate tablets approved and issued by the State Drug Administration. Toremifene is a non-steroidal tristyrene derivative that binds to estrogen receptors in a competitive manner with estrogen to prevent cancer cells from growing. Toremifene citrate tablets were developed by KYOWA KIRIN in Japan, and the trade name is FARESTON (FARESTON). China Pharmaceutical Industry Information Center PDB Drug Comprehensive Count
Express News | Morning Announcement
Osecon (002755.SZ) subsidiary announces the latest research results of the innovative drug ASKB589 at the American Society of Clinical Oncology Symposium
Osecon (002755.SZ) announced that AskGene Limited, a subsidiary of the company...
Aosaikang Pharmaceutical's Unit Gets Nod for Two Drugs
Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, received approval from China's National Medical Products Administration for the registration of two drugs. The f
Osecon (002755.SZ) subsidiary etrapopa ethanolamine tablets obtained a drug registration certificate
Zhitong Finance App News, Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for etrapoethanolamine tablets approved and issued by the State Drug Administration. The relevant indications are: This product is suitable for adults with chronic immune (idiopathic) thrombocytopenia (ITP) patients with chronic immune (idiopathic) thrombocytopenia (ITP) in children aged 6 and above who have previously had poor response to corticosteroids, immunoglobulins, etc. This product is only used in ITP patients with increased risk of bleeding due to thrombocytopenia and clinical conditions.
Analysis
Price Target
No Data
